title: Zolpidem: a review of its use in the management of insomnia.
abstract: Zolpidem (Ambien, Stilnox, Myslee, an imidazopyridine, is a nonbenzodiazepine hypnotic indicated for the short-term treatment of insomnia. Zolpidem improves sleep in patients with insomnia. Its overall tolerability is favourable when administered according to the manufacturer's prescribing information, with a low propensity to cause clinical residual effects, withdrawal, dependence or tolerance. In addition, most evidence suggests that the drug is associated with minimal rebound insomnia. In the only clinical trials that investigated the use of a hypnosedative drug in an 'as-needed' regimen, zolpidem produced a global improvement in sleep. Thus, zolpidem continues to be a useful therapeutic option in the pharmacological treatment of patients with insomnia.
authors.affiliation: Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
authors.forename: Tracy
authors.initials: T
authors.lastname: Swainston Harrison
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D000367:Age Factors; D002986:Clinical Trials as Topic / Q000379:methods; D004334:Drug Administration Schedule; D004341:Drug Evaluation / Q000379:methods; D018755:GABA Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D016896:Treatment Outcome; D000077334:Zolpidem
chemical_list: D018755:GABA Agonists; D006993:Hypnotics and Sedatives; D011725:Pyridines; D000077334:Zolpidem